Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
J Med Virol
; 92(7): 915-918, 2020 07.
Article
in English
| MEDLINE | ID: covidwho-47259
ABSTRACT
An 80-year-old man with multiple comorbidities presented to the emergency department with tachypnea, tachycardia, fever, and critically low O2 saturation and definitive chest computerized tomography scan findings in favor of COVID-19 and positive PCR results in 48 hours. He received antiviral treatment plus recombinant human erythropoietin (rhEPO) due to his severe anemia. After 7 days of treatment, he was discharged with miraculous improvement in his symptoms and hemoglobin level. We concluded that rhEPO could attenuate respiratory distress syndrome and confront the severe acute respiratory syndrome coronavirus 2 virus through multiple mechanisms including cytokine modulation, antiapoptotic effects, leukocyte release from bone marrow, and iron redistribution away from the intracellular virus.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Tachycardia
/
Erythropoietin
/
Coronavirus Infections
/
Fever
/
Tachypnea
/
Anemia
Type of study:
Case report
/
Diagnostic study
/
Experimental Studies
/
Prognostic study
Topics:
Long Covid
Country/Region as subject:
Asia
Language:
English
Journal:
J Med Virol
Year:
2020
Document Type:
Article
Affiliation country:
Jmv.25839
Similar
MEDLINE
...
LILACS
LIS